Incretin Therapies: Advances, Challenges, and Future Directions in Diabetes
Review of incretin-based therapy advancements covers dual/triple agonists, oral formulations, and combination strategies with discussion of challenges and future research directions.
Quick Facts
What This Study Found
Review of incretin-based therapy advancements covers dual/triple agonists, oral formulations, and combination strategies with discussion of challenges and future research directions.
Key Numbers
Review covers multiple drug generations — from first GLP-1 drugs through dual (GIP/GLP-1) to triple (GIP/GLP-1/glucagon) agonists.
How They Did This
Study methodology detailed in the full publication.
Why This Research Matters
Relevant to the expanding applications of peptide-based therapies in medicine.
The Bigger Picture
Contributes to the growing body of evidence for peptide therapeutics across medical specialties.
What This Study Doesn't Tell Us
Limitations discussed in the full publication.
Questions This Raises
- ?What are the long-term implications?
- ?How do results compare to existing evidence?
- ?What research is needed next?
Trust & Context
- Key Stat:
- Key finding Review of incretin-based therapy advancements covers dual/triple agonists, oral formulations, and co
- Evidence Grade:
- Evidence level based on study design.
- Study Age:
- Published in 2025.
- Original Title:
- Incretin-based therapies: advancements, challenges, and future directions in type 2 diabetes management.
- Published In:
- Journal of basic and clinical physiology and pharmacology, 36(2-3), 95-111 (2025)
- Authors:
- Alluri, Amruth A(2), Guntupalli, Yashaswi, Suvarna, Shruti Suresh, Prystupa, Yuliya, Khetan, Shrishti Prakash, Vejandla, Bharath, Babu Swathi, Naraginti Lenin
- Database ID:
- RPEP-09876
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does this mean for patients?
Review of incretin-based therapy advancements covers dual/triple agonists, oral formulations, and combination strategies with discussion of challenges and future research directions.
How reliable is this?
Consult the full publication and healthcare provider.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09876APA
Alluri, Amruth A; Guntupalli, Yashaswi; Suvarna, Shruti Suresh; Prystupa, Yuliya; Khetan, Shrishti Prakash; Vejandla, Bharath; Babu Swathi, Naraginti Lenin. (2025). Incretin-based therapies: advancements, challenges, and future directions in type 2 diabetes management.. Journal of basic and clinical physiology and pharmacology, 36(2-3), 95-111. https://doi.org/10.1515/jbcpp-2025-0031
MLA
Alluri, Amruth A, et al. "Incretin-based therapies: advancements, challenges, and future directions in type 2 diabetes management.." Journal of basic and clinical physiology and pharmacology, 2025. https://doi.org/10.1515/jbcpp-2025-0031
RethinkPeptides
RethinkPeptides Research Database. "Incretin-based therapies: advancements, challenges, and futu..." RPEP-09876. Retrieved from https://rethinkpeptides.com/research/alluri-2025-incretinbased-therapies-advancements-challenges
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.